TITLE:
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART

CONDITION:
HIV Infections

INTERVENTION:
Amprenavir/ritonavir

SUMMARY:

      The purpose of this study is to study amprenavir/ritonavir, saquinavir/ritonavir or
      efavirenz in HIV-infected patients following failure with Kaletra (ABT-378/ritonavir) as
      their first protease inhibitor based HAART.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion:

          -  Remain on present anti-HIV drugs during screening until a new regimen is started.

          -  Have a viral load of at least 1,000 copies/ml on the 2 most recent tests after at
             least 24 weeks of lopinavir/ritonavir and while still on it.

          -  Have an HIV which shows reduced susceptibility to lopinavir.

          -  Are at least 18 years old.

          -  Are not presently ill.

          -  Have not been treated for an opportunistic infection within 30 days of screening.

          -  Agree not to take certain drugs and agree to inform and get permission from the
             doctor before taking any medicines, over the counter medicines, herbal medicines,
             alcohol or recreational drugs.

          -  Agree to use an accepted barrier method of birth control.

        Exclusion:

          -  Female subject is pregnant or lactating.

          -  Have taken any protease inhibitor other than lopinavir/ritonavir for more that two
             weeks.

          -  Are taking chemotherapy.

          -  Have a medical problem with their pancreas.

          -  Have been screened for this study within the past 12 weeks.

          -  Appear to be unsuitable in the opinion of the doctor.
      
